TMDX Stock: Price, Earnings History and SEC Filings
TransMedics Group, Inc. (TMDX) last traded at $65.99, down 1.68% on the latest session and down 20.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.44 against an analyst estimate of $0.50, a miss of 12.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TMDX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $0.44 | $0.50 | -12.00% |
| Mar 2026 | May 5, 2026 | $0.30 | $0.62 | -51.61% |
| Dec 2025 | Feb 24, 2026 | $0.57 | $0.41 | +39.02% |
| Sep 2025 | Oct 29, 2025 | $0.66 | $0.37 | +78.38% |
TMDX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How TMDX reacts to earnings
Across its last 8 earnings releases, TMDX moved 9.7% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | -5.28% |
| 2026-05-05 | After close | -23.19% |
| 2026-02-27 | Before open | +7.94% |
| 2026-02-24 | After close | -4.30% |
| 2025-10-29 | After close | +1.09% |
| 2025-07-30 | After close | +10.46% |
| 2025-05-08 | After close | +19.64% |
| 2025-02-27 | After close | +5.82% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TMDX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $605M | $190M | $134M | 31.4% | $4.87 |
| 2024 | $442M | $35M | -$81M | 8.0% | $1.01 |
| 2023 | $242M | -$25M | -$165M | -10.4% | $-0.77 |
| 2022 | $93M | -$36M | -$58M | -38.8% | $-1.23 |
| 2021 | $30M | -$44M | -$32M | -146.1% | $-1.60 |
| 2020 | $26M | -$29M | -$31M | -112.1% | $-1.16 |
| 2019 | $24M | -$34M | -$32M | -142.1% | – |
| 2018 | $13M | -$24M | -$26M | -182.5% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TMDX
- 8-K · Sep 10, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · May 21, 2026Shareholder vote, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 10, 2026
- 8-K · Feb 27, 2026Results of operations, Financial statements and exhibits
- 10-K · Feb 24, 2026
- 8-K · Feb 24, 2026Results of operations, Financial statements and exhibits
Insider filing activity
TMDX insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TMDX news
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Oct 30, 2026 · finance.yahoo.com
- TransMedics to Present at Upcoming Investor ConferencesOct 29, 2026 · finance.yahoo.com
- TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026Oct 22, 2026 · finance.yahoo.com
About TransMedics Group, Inc.
TransMedics Group, Inc. (TMDX) is a US-listed public company on Nasdaq. The SEC classifies its business as Electromedical & Electrotherapeutic Apparatus. It is incorporated in MA. Its fiscal year ends in December.